Antifungal Activity of Nonantifungal Drugs
- 1 July 2003
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 22 (7), 397-407
- https://doi.org/10.1007/s10096-003-0947-x
Abstract
The antifungal activity of synthetic, nonchemotherapeutic compounds, antineoplastic agents and antibacterial drugs, such as sulphonamides, has been known since the early 20th century (1932). In this context, the term "nonantifungal" is taken to include a variety of compounds that are employed in the management of pathological conditions of nonfungal infectious etiology but have been shown to exhibit broad-spectrum antifungal activity. In this review, the antifungal properties of compounds such as chlorpromazine, proton pump inhibitors, antiarrhythmic agents, cholesterol-lowering agents, antineoplastic and immunosuppressive agents, antiparasitic drugs and antibiotics are described. Since fungi are eukaryotic cells, they share many pathways with human cells, thus increasing the probability of antifungal activity of "nonfungal drugs". The potential of these drugs for treatment of fungal infections has been investigated sporadically using the drugs alone or in combination with "classic" antifungal agents. A review of the literature, supplemented with a number of more recent investigations, suggests that some of these compounds enhance the activity of conventional antifungal agents, eliminate natural resistance to specific antifungal drugs (reversal of resistance) or exhibit strong activity against certain fungal strains in vitro and in animal models. The role of these agents in the epidemiology and in the clinical manifestations of fungal infections and the potential of certain drugs for treatment of invasive fungal infections require further investigation.Keywords
This publication has 94 references indexed in Scilit:
- In Vitro Synergistic Interaction between Amphotericin B and Pentamidine against Scedosporium prolificansAntimicrobial Agents and Chemotherapy, 2002
- Cryptococcus neoformansInfection in Organ Transplant Recipients: Variables Influencing Clinical Characteristics and OutcomeEmerging Infectious Diseases, 2001
- Prevention of invasive aspergillosis in AIDS by sulfamethoxazoleAIDS, 2001
- A Randomized Trial of Daily and Thrice‐Weekly Trimethoprim‐Sulfamethoxazole for the Prevention ofPneumocystis cariniiPneumonia in Human Immunodeficiency Virus‐Infected PersonsClinical Infectious Diseases, 1999
- Invasive Aspergillosis in Mice Immunosuppressed with Cyclosporin A, Tacrolimus (FK506), or Sirolimus (Rapamycin)The Journal of Infectious Diseases, 1997
- The effect of nebulised pentamidine on the concentration of intra-oral Candida albicans in HIV-infected patientsJournal of Medical Microbiology, 1994
- Modification of responses of Candida albicans to cisplatin by membrane damaging antimycotic agentsMycoses, 1991
- Combinations of Antifungal and Antineoplastic Drugs with Interactive Effects on Inhibition of Yeast GrowthChemotherapy, 1990
- Combined activity of ketoconazole and sulphamethoxazole against Candida albicansJournal of Antimicrobial Chemotherapy, 1982
- Amphotericin B Potentiation of Rifampicin as an Antifungal Agent against the Yeast Phase of Histoplasma capsulatumScience, 1972